Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563738 · ClinicalTrials.gov registry record · Phase 1
A 2-part Phase 1/2 Open-label Trial on ODM-212
A Phase 1 study, sponsored by Orion Corporation, Orion Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT07563738 is a Phase 1 study that is actively recruiting participants, run by Orion Corporation, Orion Pharma. The registered enrollment target is 229 participants.
The verdict
NCT07563738, a Phase 1 study, is actively recruiting participants, sponsored by Orion Corporation, Orion Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Interventions
- DRUG sotorasib
- DRUG ODM-212
- DRUG Ipilimumab and nivolumab
- DRUG Gemcitabine and nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07563738
The ClinicalTrials.gov registry entry for NCT07563738 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orion Corporation, Orion Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sotorasib is the first listed.
NCT07563738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07563738 about?
NCT07563738 is a clinical study titled "A 2-part Phase 1/2 Open-label Trial on ODM-212". An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
What is the current status of trial NCT07563738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2026-03-27. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07563738?
The interventions under investigation include: sotorasib (DRUG), ODM-212 (DRUG), Ipilimumab and nivolumab (DRUG), Gemcitabine and nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT07563738?
This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.